Novartis AG's farnesoid X receptor (FXR) agonists represent "an excellent first opportunity for combination products" in liver disease, Conatus Pharmaceuticals Inc. CEO Steven Mento told BioWorld Today, but not necessarily the only prospect for pairing with oral pan-caspase inhibitor emricasan. "There could be others."